Compare RRC & PODD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RRC | PODD |
|---|---|---|
| Founded | 1976 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Medical/Dental Instruments |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.1B | 10.3B |
| IPO Year | 1996 | 2007 |
| Metric | RRC | PODD |
|---|---|---|
| Price | $37.81 | $164.48 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 18 | 21 |
| Target Price | $43.67 | ★ $341.48 |
| AVG Volume (30 Days) | ★ 3.1M | 1.5M |
| Earning Date | 04-21-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.92% | N/A |
| EPS Growth | ★ 151.38 | N/A |
| EPS | ★ 1.44 | 1.30 |
| Revenue | ★ $3,115,515,000.00 | $2,708,100,000.00 |
| Revenue This Year | $15.60 | $24.55 |
| Revenue Next Year | $9.73 | $19.18 |
| P/E Ratio | ★ $26.22 | $126.48 |
| Revenue Growth | 28.90 | ★ 30.73 |
| 52 Week Low | $32.60 | $138.79 |
| 52 Week High | $48.31 | $354.88 |
| Indicator | RRC | PODD |
|---|---|---|
| Relative Strength Index (RSI) | 47.66 | 59.70 |
| Support Level | $37.07 | $141.67 |
| Resistance Level | $38.21 | $205.95 |
| Average True Range (ATR) | 0.94 | 5.48 |
| MACD | 0.17 | 2.61 |
| Stochastic Oscillator | 65.28 | 88.49 |
Range Resources is an exploration and production firm whose operations represent a pure play in the Marcellus shale, located in the Appalachian region of Southwest Pennsylvania. The company went public as Lomak Petroleum in 1980 and later reorganized as Range Resources in 1998. After an expensive 10-year venture with a multi-basin strategy, Range Resources found its identity as an Appalachian natural gas producer, offloading its Permian assets in 2013. Range quickly became a leading US gas producer after its merger with Memorial Resource Development in 2016. Following the merger, Range saw its operational unit costs rise to an uncompetitive level and subsequently sold the assets in 2020 to return to its roots as an Appalachian producer.
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.